Latest Symphony Dynamo Inc. Stories

2008-11-06 18:00:22

Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that it will present at the Credit Suisse 2008 Healthcare Conference on Wednesday, November 12, 2008 at 3:00 p.m. MST (2:00 p.m. PST) in Phoenix, Arizona. Dino Dina, M.D., President and Chief Executive Officer, will present a corporate overview of Dynavax. The presentation will be webcast. To access the live audio broadcast and the subsequent archived audio recording of the presentation, please log onto the company's website...

2008-10-30 18:00:29

Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that it plans to report third quarter 2008 financial results before the market opens on Monday, November 3, 2008. The company also plans to have a corporate overview presentation at the Oppenheimer 19th Annual Healthcare Conference in New York City on November 3, 2008 at 11:20 a.m. EST (8:20 a.m. PST). Michael S. Ostrach, Vice President and Chief Business Officer of Dynavax, will present at this conference. To access the live...

2008-10-21 18:00:25

Dynavax Technologies Corporation (NASDAQ:DVAX) and Merck & Co., Inc. have received communication from the U.S. Food and Drug Administration (FDA) regarding the two companies' response to the agency's request for safety information relating to the clinical hold on the two Investigational New Drug (IND) Applications for HEPLISAV(TM), an investigational hepatitis B virus (HBV) vaccine. The FDA has advised the companies that the balance of risk versus potential benefit no longer favors...

2008-09-29 09:00:57

Dynavax Technologies Corporation (NASDAQ:DVAX) today announced it has been awarded a $17 million contract to develop its advanced immunostimulatory sequences (ISS) technology using Toll-Like Receptor 9 (TLR9) agonists as vaccine adjuvants. This five-year contract was awarded by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop novel vaccine adjuvant candidates that signal through receptors of the innate immune system. The...

2008-08-05 18:00:40

Dynavax Technologies Corporation (Nasdaq:DVAX) and Merck & Co., Inc. announced today top-line immunogenicity results from a Phase 3 clinical trial comparing HEPLISAV(TM), an investigational hepatitis B virus (HBV) vaccine, to a currently marketed HBV vaccine, Engerix-B(R) (1). The study achieved its primary endpoint. HEPLISAV is being jointly developed by Dynavax and Merck for use in adults and in patients with end stage renal disease. This study, called PHAST (Phase 3 HeplisAv...

2008-07-23 18:00:53

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced an agreement with Novartis Vaccines and Diagnostics, Inc. for the supply and development, and possible commercialization, of Dynavax's novel Universal Influenza Vaccine in collaboration with Novartis. Under the agreement Novartis will provide Dynavax a supply of trivalent influenza vaccine, an essential component of Dynavax's Universal Influenza Vaccine, for both clinical trial use and vaccine sales. Novartis receives an exclusive...

Word of the Day
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.